Bi-Layer NO–Tranexamic Acid–Propolis Dressings for Rapid Hemostasis

Study Background and Research Question

Trauma-related injuries remain a leading cause of mortality, with uncontrolled hemorrhage and infection jointly responsible for a significant majority of early deaths following severe injury. In the United States, trauma accounts for roughly 10% of annual deaths, with excessive blood loss and wound infection being the primary threats in both civilian and military settings. Hemorrhagic instability can result in fatality within hours, while infection risk rises sharply within the first 72 hours post-injury, often complicating wound healing and increasing morbidity. Despite advances in emergency medicine, there is a persistent need for wound dressings that can both rapidly stabilize bleeding and reduce infection risk at the site of trauma. The reference study by Nguyen et al. addresses this critical challenge by engineering an advanced wound dressing capable of inducing instant clot formation while simultaneously delivering robust antibacterial action. The central research question investigates whether integrating an antifibrinolytic agent, nitric oxide (NO) donor, and propolis can create a synergistic system for effective trauma intervention (details).

Key Innovation from the Reference Study

The primary innovation lies in the creation of a bi-layer wound dressing that unites three functional components: tranexamic acid (TXA) as an antifibrinolytic agent, an NO donor (S-nitroso-N-acetylpenicillamine, SNAP), and propolis, a natural bioadhesive with antimicrobial and anti-inflammatory properties. The design is strategically layered: the wound-contacting surface incorporates TXA suspended in propolis, while the base layer, positioned away from the wound, embeds SNAP within a Carbosil® polymer matrix. This configuration achieves two simultaneous goals: TXA prevents fibrinolysis and stabilizes clot formation at the wound interface, while NO and propolis provide broad-spectrum antibacterial activity. By synchronizing these mechanisms, the dressing offers immediate hemostatic action and mitigates the risk of infection, directly targeting the two most lethal factors in trauma wound management (see comparison).

Methods and Experimental Design Insights

The fabrication process involved layering TXA and propolis in varying concentrations (2.5%, 5.0%, and 7.5% vol/vol propolis) atop the Carbosil®-SNAP base. The experimental workflow was designed to assess both hemostatic efficiency and antibacterial capacity:

• Platelet adhesion and clot formation were evaluated using a lactate dehydrogenase-based assay, measuring the degree and rate of fibrin activation.
• Scanning electron microscopy (SEM) was employed to visualize the microstructure of the clot matrix, confirming the density and stability of the fibrin network formed by the dressing.
• Antibacterial efficacy was quantified by measuring colony-forming units (CFU) of Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii after exposure to the dressing.
• Comparative controls included dressings lacking TXA and/or NO donor to isolate the contribution of each functional element.

The assessment focused on immediate clotting kinetics (within 15 minutes of application) and bacterial reduction percentages, aligning with clinical priorities in trauma care.

Protocol Parameters

• Layer configuration: Apply the TXA–propolis layer directly to the wound; SNAP–Carbosil® forms the base.
• Propolis content: Tested at 2.5%, 5.0%, and 7.5% (vol/vol); 7.5% yielded optimal fibrin activation.
• Tranexamic Acid use: Uniform layer integration; concentration tailored for rapid clot stabilization, modeling literature concentrations between 5–10 mM for maximal plasmin inhibition.
• Antibacterial assay: Incubate dressings with 10⁶ CFU/mL bacterial suspension for 24 hours; enumerate CFU post-incubation.
• SEM preparation: Fix dressings post-clotting assay and dehydrate prior to imaging to preserve fibrin architecture.

Core Findings and Why They Matter

The study's major findings highlight the synergistic benefits of the bi-layer system:

• Enhanced Hemostatic Activity: The 7.5% propolis-TXA configuration demonstrated a significant increase in fibrin activation within 15 minutes, outperforming controls without TXA. SEM images revealed a dense, stable fibrin network, confirming the antifibrinolytic action of TXA in situ. This rapid clot stabilization is crucial for preventing exsanguination in trauma scenarios (reference).
• Potent Antibacterial Efficacy: The combined action of NO and propolis led to a 98.9 ± 1% reduction in S. aureus and a 99.4 ± 1% reduction in multidrug-resistant A. baumannii CFU, offering broad-spectrum protection against common and resistant pathogens.
• Dual-Action Mechanism: The integration of antifibrinolytic and antimicrobial strategies addresses both primary trauma threats in a single dressing, streamlining emergency wound management.

These outcomes underscore the translational potential for the dressing in both civilian emergency and combat care settings, where time-to-hemostasis and infection control can be decisive for patient survival.

Comparison with Existing Internal Articles

Several recent reviews and workflow articles support and contextualize the reference study’s findings:

• Tranexamic Acid: Antifibrinolytic Agent for Rapid Clot Formation offers protocols for optimizing clot stabilization in trauma and wound healing models, emphasizing the importance of dosing and integration methods for antifibrinolytic agents.
• Tranexamic Acid in Fibrinolysis Research: Protocols and Innovation details the growing role of high-purity TXA in advanced hemostasis research, providing stepwise workflows for plasmin-induced neutrophil adherence assays and clotting models. The present study’s bi-layer dressing expands on these approaches by combining TXA with NO donors and bioadhesives for enhanced trauma application.
• Bi-Layer Wound Dressings: Tranexamic Acid and NO for Hemostasis summarizes the dual-action concept, highlighting the translational relevance of integrating antifibrinolytic and antimicrobial strategies in a single device.

Together, these resources illustrate a broader trend toward multifunctional wound care platforms, with the reference study providing a robust proof-of-concept for future translational research and product development.

Limitations and Transferability

While the referenced dressing demonstrates clear advantages in preclinical models, several limitations must be acknowledged:

• In vivo validation: The majority of data derive from in vitro and ex vivo assays. Clinical efficacy, safety, and scalability require further animal studies and eventual human trials.
• Material variability: The use of natural propolis introduces batch-to-batch variability that may affect reproducibility and regulatory approval.
• Complex wound environments: Real-world trauma wounds may present with diverse tissue types, contaminants, and mechanical stresses not fully replicated in controlled assays.

Nevertheless, the modular nature of the bi-layer design supports potential adaptation to different wound types and clinical contexts, pending further validation.

Research Support Resources

Researchers seeking to replicate or extend these findings can employ high-purity antifibrinolytic agents such as Tranexamic Acid (SKU B1858) to model clot stabilization and inhibition of fibrinolysis in wound healing and trauma studies. The product dossier details optimal storage, solubility, and usage guidelines to ensure reproducibility. When designing similar bi-layer dressings or conducting plasmin-induced neutrophil adherence assays, careful titration of Tranexamic Acid concentrations (for example, in the range of 5–10 mM) is recommended for robust inhibition of fibrinolysis, as supported by both the product information and recent literature. For further protocol optimization and troubleshooting, the internal resources referenced above provide detailed experimental workflows and practical insights for advanced fibrinolysis research.